文献速递白血病

维奈克拉联合去甲基化药物治疗新诊断急性髓系白血病:7天、14天、21天与28天周期的ELN和Mayo遗传风险分层分析(540例)

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.
PubMed 文献 · Am J Hematol · 2026-09-17

在540例新诊断急性髓系白血病患者中,比较维奈克拉联合去甲基化药物第一周期7天、14天、21天和28天方案,中位随访37.7个月,移植后生存在各方案间无显著差异,预后主要由ELN 2024和Mayo遗传风险决定。

要点

  • 各维奈克拉时长组移植后中位生存无显著差异(13.3、11.9、16.8、13.2个月,p=0.65)。
  • ELN高危患者中14天方案移植后生存劣于21天和28天方案(p<0.01)。
  • 预后主要由ELN和Mayo遗传风险决定,而非维奈克拉时长。

核心结论

  • 新诊断急性髓系白血病患者中,维奈克拉7、14、21、28天方案移植后生存无显著差异,预后主要由遗传风险决定。

研究设计与样本

  • Mayo Clinic单中心回顾性研究,纳入540例接受维奈克拉联合去甲基化药物治疗的新诊断急性髓系白血病患者。
  • 第一周期维奈克拉时长:7天(n=33)、14天(n=117)、21天(n=96)、28天(n=294),按ELN 2024和Mayo遗传风险分层。

主要发现

  • 中位随访37.7个月,各组异基因造血干细胞移植率相似(7/14/21/28天分别为15%、18%、18%、20%,p=0.86)。
  • 移植后中位生存各组相当(7/14/21/28天分别为13.3、11.9、16.8、13.2个月,p=0.65)。
  • 生存随ELN风险显著变化(高危6.3、中危11.5、低危18.3个月,p<0.01),Mayo遗传风险亦显著(6.9、17.8个月、未达到,p<0.01)。
  • ELN高危患者中,14天维奈克拉的移植后生存劣于21天和28天方案(p<0.01)。
  • 30天和60天死亡率在较短维奈克拉方案中更高(7天:9%/18%;14天:7%/15%;28天:2%/6%)。

临床怎么用

  • 维奈克拉联合去甲基化药物治疗新诊断急性髓系白血病时,7至28天方案均可考虑,但ELN高危患者应避免14天方案。
  • 治疗决策应基于ELN 2024和Mayo遗传风险分层,而非维奈克拉时长。

局限性

  • 回顾性研究,治疗选择可能存在偏倚,尤其短疗程组30/60天死亡率较高可能反映选择偏倚。
  • 需前瞻性试验确立风险适配的维奈克拉剂量策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with newly-diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND-AML patients receiving Ven-HMA at Mayo Clinic, outcomes were compared across Ven 7- (n = 33), 14- (n = 117), 21- (n = 96), and 28-day (n = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow-up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7-, 14-, 21-, and 28-day; p = 0.86). Median transplant-censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; p = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; p < 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; p < 0.01). Survival was comparable across Ven durations within ELN intermediate/low-risk and all Mayo risk groups. Among ELN high-risk patients, 14-day Ven was associated with inferior transplant-censored survival compared to 21- and 28-day schedules (p < 0.01). Notably, 30- and 60-day mortality were higher with shorter Ven schedules (7-day: 9%/18%; 14-day: 7%/15%) versus 28-day (2%/6%), which likely reflects treatment selection bias. In ND-AML, no significant difference in transplant-censored survival was observed across the 7-, 14-, 21-, and 28-day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk-adapted Ven dosing strategies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kumar S, Warraich M, Fatima M, et al. Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients. Am J Hematol. 2026. PMID: 42755126. doi:10.1002/ajh.70500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。